Moderna Surges Over 80% in Pre-Market Trading as mRNA Cancer Vaccine Succeeds in Phase 3 Trial, Marking Historic Breakthrough in Melanoma Treatment
Moderna and Merck announced on Wednesday that their jointly developed personalized mRNA cancer vaccine achieved positive results in a large Phase 3 clinical trial, marking the first successful…
Moderna and Merck announced on Wednesday that their jointly developed personalized mRNA cancer vaccine achieved positive results in a large Phase 3 clinical trial, marking the first successful Phase 3 trial for mRNA technology in cancer treatment and a major breakthrough in personalized immunotherapy in the history of cancer therapy.
Original: https://wallstreetcn.com/articles/3779803
insigtX content is informational and educational, not investment advice.